These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 7811540)

  • 21. Prevalence and clinical significance of zidovudine resistance mutations in human immunodeficiency virus isolated from patients after long-term zidovudine treatment. AIDS Clinical Trials Group 116B/117 Study Team and the Virology Committee Resistance Working Group.
    Japour AJ; Welles S; D'Aquila RT; Johnson VA; Richman DD; Coombs RW; Reichelderfer PS; Kahn JO; Crumpacker CS; Kuritzkes DR
    J Infect Dis; 1995 May; 171(5):1172-9. PubMed ID: 7538548
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Update on nevirapine: quest for a niche.
    MacDougall DS
    J Int Assoc Physicians AIDS Care; 1997 Sep; 3(9):37-43. PubMed ID: 11364713
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antiretroviral drugs: new agents, new combinations line up against HIV.
    Phillips L
    Hosp Technol Ser; 1996 Jan; 15(1):1-3. PubMed ID: 10161344
    [No Abstract]   [Full Text] [Related]  

  • 24. Current clinical experience with nevirapine for HIV infection.
    Carr A; Cooper DA
    Adv Exp Med Biol; 1996; 394():299-304. PubMed ID: 8815694
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antiretroviral drug resistance.
    Japour AJ
    AIDS Clin Care; 1995 Aug; 7(8):63-5, 67. PubMed ID: 11362787
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Convergent combination therapy can select viable multidrug-resistant HIV-1 in vitro.
    Larder BA; Kellam P; Kemp SD
    Nature; 1993 Sep; 365(6445):451-3. PubMed ID: 7692302
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of lamivudine in HIV-infected persons with prior exposure to zidovudine/didanosine or zidovudine/zalcitabine.
    Albrecht MA; Hughes MD; Liou SH; Katzenstein DA; Murphy R; Balfour HH; Para MF; Valdez H; Hammer SM;
    AIDS Res Hum Retroviruses; 2000 Sep; 16(14):1337-44. PubMed ID: 11018853
    [TBL] [Abstract][Full Text] [Related]  

  • 28. ddC (zalcitabine).
    Skowron G
    Adv Exp Med Biol; 1996; 394():257-69. PubMed ID: 8815690
    [No Abstract]   [Full Text] [Related]  

  • 29. Roaches of inner space.
    Gilden D
    GMHC Treat Issues; 1995 Oct; 9(10):1, 14-6. PubMed ID: 11362912
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group.
    Collier AC; Coombs RW; Schoenfeld DA; Bassett RL; Timpone J; Baruch A; Jones M; Facey K; Whitacre C; McAuliffe VJ; Friedman HM; Merigan TC; Reichman RC; Hooper C; Corey L
    N Engl J Med; 1996 Apr; 334(16):1011-7. PubMed ID: 8598838
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Quantitative analysis of the endogenous reverse transcriptase reactions of HIV type 1 variants with decreased susceptibility to azidothymidine and nevirapine.
    Krogstad P; Chen IS; Canon J; Rey O
    AIDS Res Hum Retroviruses; 1996 Jul; 12(11):977-83. PubMed ID: 8827213
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nevirapine surprise.
    Smart T
    GMHC Treat Issues; 1996; 10(6/7):25. PubMed ID: 11363640
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Viral resistance and the selection of antiretroviral combinations.
    Larder BA
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 1():S28-33. PubMed ID: 8595505
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mutations linked to drug resistance, human immunodeficiency virus type 1 biologic phenotype and their association with disease progression in children receiving nucleoside reverse transcriptase inhibitors.
    Englund JA; Raskino C; Vavro C; Palumbo P; Ross LL; McKinney R; Nikolic-Djokic D; Colgrove RC; Baker CJ;
    Pediatr Infect Dis J; 2004 Jan; 23(1):15-22. PubMed ID: 14743040
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nucleoside reverse transcriptase inhibitors and resistance of human immunodeficiency virus type 1.
    Johnson VA
    J Infect Dis; 1995 Mar; 171 Suppl 2():S140-9. PubMed ID: 7861019
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prevalence of genotypic resistance to nucleoside analogues in antiretroviral-naive and antiretroviral-experienced HIV-infected patients in Spain.
    Gómez-Cano M; Rubio A; Puig T; Pérez-Olmeda M; Ruiz L; Soriano V; Pineda JA; Zamora L; Xaus N; Clotet B; Leal M
    AIDS; 1998 Jun; 12(9):1015-20. PubMed ID: 9662197
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An interview with Charles A.B. Boucher, MD, PhD. Interview by Mark Mascolini.
    Boucher CA
    J Int Assoc Physicians AIDS Care; 1995 Nov; 1(10):30-5. PubMed ID: 11362972
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Non-nucleoside reverse transcriptase inhibitors.
    Bowers M
    BETA; 1996 Jun; ():19-22. PubMed ID: 11363645
    [TBL] [Abstract][Full Text] [Related]  

  • 39. What we know about anti-HIV drugs.
    Treat Rev; 1995 May; (no 18):3-4. PubMed ID: 11362592
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Therapy of HIV infection with nucleoside analogs].
    Jablonowski H; Mauss S; Armbrecht C; Manegold C; Szelenyi H; Hengels KJ
    Z Gastroenterol; 1993 Nov; 31 Suppl 5():60-6. PubMed ID: 8197806
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.